| Título: | Medium-term clinical outcomes following Xen45 device implantation |
| Autores: | Fernández García, Aitor ; Zhou, Ying ; García Alonso, Mercedes ; Andrango, Henry D. ; Poyales Galán, Francisco ; Garzón Jiménez, Nuria |
| Tipo de documento: | texto impreso |
| Editorial: | Springer Verlag, 2019-11 |
| Dimensiones: | application/pdf |
| Nota general: | info:eu-repo/semantics/openAccess |
| Idiomas: | |
| Palabras clave: | Estado = Publicado , Materia = Ciencias Biomédicas: Medicina: Cirugía , Materia = Ciencias Biomédicas: Medicina: Oftalmología , Tipo = Artículo |
| Resumen: |
Purpose: To evaluate medium-term clinical outcomes with microstent XEN® 45 Gel Stent (Allergan Dublin, Ireland) for treatment of primary open-angle glaucoma (POAG). Material and methods: This is a retrospective, descriptive and observational study involving 93 eyes from 63 patients who had undergone POAG surgery with a XEN® 45 Gel Stent implantation and had been followed up and controlled between 12 and 36 months. Results: IOP dropped from 18.23?±?5.00 mmHg pre-op to 14.16?±?2.14, 14.47?±?2.16 and 14.63?±?1.91 at 1, 2 and 3 years after surgery (p?=?0.000, 0.000 and 0.001) consecutively. Mean number of medications dropped from 1.87?±?0.94 preoperatively to 0.31?±?0.69, 0.34?±?0.63 and 1.00?±?0.88 (p?=?0.000, 0.000 and 0.017) at 12, 24 and 36 months. Mean visual field deviation values never turned out to be significant for any of the follow-up visit data. A total of 94.6% of the surgical procedures turned out to be complication-free. In one surgery, the procedure failed and 18 months later other device was implanted. Conclusion: POAG surgical procedures with XEN® 45 Gel Stent implants are a safe and effective treatment approach. |
| En línea: | https://eprints.ucm.es/58079/1/Nuria%20Garz%C3%B3n_ACFrOgBYmCQ8nY3DY0VVtn1SXLp40-Y1uo9ilTeTfpw2KsiwJZT_AZa9GAcmn0lxSB7iqsE-9Xi2x5eTVj6ZIbq3DMJuSGi04UaUG2EavZHShBJ_N3flppRweq14Cxc%3D.pdf |
Ejemplares
| Estado |
|---|
| ningún ejemplar |
